Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, P. R. China.
Lipids Health Dis. 2020 May 23;19(1):103. doi: 10.1186/s12944-020-01254-2.
This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia.
Type 2 diabetic patients (56) with microalbuminuria and hypertriglyceridemia aged 30 to 75 were randomly divided into the fenofibrate treatment group(n = 28) and the control group (n = 28) for 180 days. Urinary microalbumin /creatinine ratio (UACR) and other metabolic parameters were compared at baseline, during treatment and after treatment.
After 180 days, the reduction of level of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) between two groups showed no difference. In the treatment group, uric acid (UA) (296.42 ± 56.41 vs 372.46 ± 72.78), triglyceride (TG) [1.51(1.17, 2.06) vs 3.04(2.21, 3.29)], and UACR [36.45 (15.78,102.41) vs 129.00 (53.00, 226.25)] were significantly decreased compared with the baseline. The high-density lipoprotein cholesterol (HDL-C) levels were significantly increased (1.22 ± 0.26 vs 1.09 ± 0.24) compared with the baseline. The decrease in UACR [- 44.05(- 179.47, - 12.16) vs - 8.15(- 59.69, 41.94)]in treatment group was significantly higher compared with the control group. The decrease in UACR was positively associated with the decreases in TG (r = 0.447, P = 0.042) and UA (r = 0.478, P = 0.024) after fenofibrate treatment.
In the patients with hypertriglyceridemia and type 2 diabetes mellitus, fenofibrate can improve microalbuminuria and do not increase the deterioration of glomerular filtration rate.
ClinicalTrials.gov identifier: NCT02314533, 2014.12.9.
本研究旨在探讨非诺贝特治疗 2 型糖尿病伴高甘油三酯血症患者微量白蛋白尿的疗效。
将年龄在 30-75 岁之间的 56 例伴有微量白蛋白尿和高甘油三酯血症的 2 型糖尿病患者随机分为非诺贝特治疗组（n=28）和对照组（n=28），治疗 180 天。比较两组患者在基线、治疗期间和治疗后的尿微量白蛋白/肌酐比值（UACR）和其他代谢参数。
180 天后，两组空腹血糖（FBG）和糖化血红蛋白（HbA1c）水平的降低无差异。治疗组尿酸（UA）（296.42±56.41 与 372.46±72.78）、甘油三酯（TG）[1.51（1.17，2.06）与 3.04（2.21，3.29）]和 UACR[36.45（15.78，102.41）与 129.00（53.00，226.25）]均较基线明显降低。高密度脂蛋白胆固醇（HDL-C）水平较基线明显升高（1.22±0.26 与 1.09±0.24）。与对照组相比，治疗组 UACR 的降低幅度[-44.05（-179.47，-12.16）与-8.15（-59.69，41.94）]差异有统计学意义。治疗后，UACR 的降低与 TG（r=0.447，P=0.042）和 UA（r=0.478，P=0.024）的降低呈正相关。
在伴有高甘油三酯血症的 2 型糖尿病患者中，非诺贝特可改善微量白蛋白尿，且不会加重肾小球滤过率恶化。
ClinicalTrials.gov 标识符：NCT02314533，2014.12.9。
